HONG KONG and SHANGHAI, June 24, 2026 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An" or the "Group"; HKEX: 2318/82318; SSE: 601318) attended the World Economic Forum's 17th Annual Meeting of the New Champions, also known as Summer Davos 2026, convened at the Dalian International Conference Center on 23 June, 2026. This year's forum brought together more than 1,700 representatives from over 90 countries and regions to discuss cutting-edge topics related to global economy, technology, and social development. Among the key topics were ageing population and the sustainable development of a longevity society.

He Mingke, CEO of Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor"; HKEX: 1833), the flagship of Ping An Group's health and senior care ecosystem, shared insights on Ping An's full-cycle health and longevity management solutions under its "integrated finance + health and senior care" strategy, with a focus on population aging and the sustainable development of a longevity society.

Ping An Good Doctor to Launch Health Longevity Index and Upgrade Longevity Management Services

"China is entering its own 'longevity era', and the focus of population health management is shifting from simply extending lifespan to extending healthy lifespan. The average life expectancy of Chinese residents is now close to 79 years, while healthy life expectancy remains below 69 years, leaving a health deficit of approximately 10 years. Traditional passive healthcare and post-incident claims settlement alone are no longer sufficient to meet the health needs arising from longevity. What is needed is more proactive health management, with earlier intervention to delay functional decline, reduce the risk of disability, and help more people maintain good health over a longer life course," said He Mingke, CEO of Ping An Healthcare and Technology Company Limited.

Based on this insight, Ping An Good Doctor will jointly release white paper titled Centenarian Health Standards: From Passive Healthcare to a Proactive Health Paradigm with the Asia-Pacific Longevity Medicine Society, and will take the lead in launching the "China Health Longevity Index (CHLI)". Ping An Good Doctor will also upgrade the "Ping An Longevity Management Service System", promoting the shift of health management from fragmented wellness practices to systematic management, and from "treating illness and providing elderly care" to "healthy aging".

Advancing the "Integrated Finance + Health and Senior Care" Strategy

In recent years, Ping An has continued to advance its "integrated finance + health and senior care" strategy, with the upgrade of the "Ping An Longevity Management Service System" serving as a key customer-centric initiative. It is designed to promote deeper synergy between financial protection and health and senior care services, transforming insurance policies into more frequent, heartwarming companionship and helping customers enjoy healthier, higher quality lives.

Since 2026, Ping An has launched a range of services, including AI-powered Express Service, which enables customers to "get things done with one sentence", its Global Emergency Assistance service, which enables customers to "respond to emergencies with one button", and "Ping An Home-based Services". These initiatives reflect Ping An's active response to customers' evolving needs in financial services, travel safety, health, and senior care. Looking ahead, the Group will continue to deepen its "integrated finance + health and senior care" strategy, further advance the "finance + services" model and product innovation, and bring greater wellbeing to more families through Ping An's services.

- End -

About Ping An Insurance (Group) Company of China, Ltd.

Ping An Insurance (Group) Company of China, Ltd. (HKEX:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services. Under the technology-enabled "integrated finance + health and senior care" dual-pronged strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its over 250 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of December 2025, Ping An had more than RMB13 trillion in total assets. The Group ranked 27th in the Forbes Global 2000 list in 2025, 47th in the Fortune Global 500 list in 2025, and ranked AAA in MSCI ESG Ratings in 2025.

For more information, please visit the www.group.pingan.com and follow our LinkedIn page - PING AN.

上海2026年6月24日 /美通社/ -- 雲頂新耀（HKEX 1952.HK）是一家專注於創新藥研發、臨床開發、製造及商業化的生物製藥公司，今日宣佈，自耐賦康^®上市以來惠及了廣大的IgA腎病患者，為進一步擴大患者用藥可及性，公司與海南合瑞製藥股份有限公司（以下簡稱「海南合瑞」）就耐賦康^®（布地奈德腸溶膠囊）相關專利達成諒解，並就海南合瑞於2025年12月獲得中國國家藥品監督管理局批准的布地奈德腸溶膠囊開展商業化合作。

根據本次合作，海南合瑞的布地奈德腸溶膠囊將獲准在中國大陸市場上市，由雲頂新耀負責其商業化。雲頂新耀將對海南合瑞的生產及供應進行嚴格的技術指導與質量審計。該合作將有助於提升患者對耐賦康^®與海南合瑞布地奈德腸溶膠囊的用藥選擇。本次合作需滿足慣例交割條件後方可生效。

關於耐賦康^®（NEFECON^®）

耐賦康^®(NEFECON^®)是布地奈德腸溶膠囊，作為全球首個對因治療IgA腎病的藥物，是靶向腸道黏膜B細胞的免疫調節劑，能減少50%腎功能下降^[1]，在中國人群中能延緩腎功能衰退達66%^[2]，預計將疾病進展至透析或腎移植的時間延緩12.8年^[3]。同時布地奈德首過代謝率達90%^[4]，具有良好的安全性。耐賦康^®專為IgA腎病患者研製，每顆膠囊含布地奈德4mg，通過特殊的遲釋及緩釋雙重制劑工藝，將布地奈德三層包衣微丸靶向釋放於迴腸末端的黏膜B細胞（包括派爾集合淋巴結），三層包衣微丸持續穩定釋放布地奈德，高濃度覆蓋整個靶區域，從而減少誘發IgA腎病的半乳糖缺陷的IgA1（Gd-IgA1）產生，進而干預發病機制上游階段，達到治療IgA腎病的作用。

2019年6月，雲頂新耀與Calliditas Therapeutics 簽訂獨家授權許可協議，獲得在大中華地區和新加坡開發以及商業化耐賦康^®的權利。該協議於2022年3月擴展，將韓國納入雲頂新耀的授權許可範圍。

關於雲頂新耀

雲頂新耀是一家專注於創新藥研發、臨床開發、製造和商業化的生物製藥公司，致力於滿足全球市場尚未滿足的醫療需求。雲頂新耀的管理團隊在中國及全球領先製藥企業擁有深厚的專長和豐富的經驗。公司在浙江嘉善擁有具備商業化規模的全球生產基地，並依據中國、美國及歐盟標準建立了完善的GMP生產質量管理體系。

公司聚焦自身免疫、眼科、急重症及CKM（心血管、腎臟及代謝）等疾病治療領域，已打造集全渠道商業化體系與藥品全生命週期商業化能力於一體的商業化平台，並以擁有全球權益的自研mRNA平台為基礎，持續推進mRNA in vivo CAR-T與mRNA腫瘤疫苗等現有管線，同時通過引進及生態孵化潛力平台，拓展研發能力，同時強化全球化佈局，加快國際化發展進程。更多信息，請訪問公司官網：www.everestmedicines.com。

前瞻性聲明
本新聞稿所發佈的信息中可能會包含某些前瞻性表述，乃基於本公司或管理層在做出表述時對公司業務運營情況及財務狀況的現有看法、相信、和現有預期，可能會使用「將」、「預期」、「預測」、「期望」、「打算」、「計劃」、「相信」、「預估」、「確信」及其他類似詞語進行表述。這些前瞻性表述並非對未來業績的保證，會受到風險、不確定性及其他因素的影響，有些乃超出本公司的控制範圍，難以預計。因此，受我們的業務、競爭環境、政治、經濟、法律和社會情況的未來變化及發展等各種因素及假設的影響，實際結果可能會與前瞻性表述所含資料有較大差別。本公司及各附屬公司、各位董事、管理人員、顧問及代理未曾且概不承擔更新該稿件所載前瞻性表述以反映在本新聞稿發佈日後最新信息、未來項目或情形的任何義務，除非法律要求。

參考文獻

1.Lafayette R,et al. Lancet. 2023 Sep 9;402(10405):859-870.

2. Zhang H, et al. Kidney360. 2024 Dec 1;5(12):1881-1892.

3.Jonathan Barratt,et al. 2023 ASN. Poster no. SA-PO886.

4.Edsbäcker S,et al. Aliment Pharmacol Ther. 1999 Feb;13(2):219-24.

SHANGHAI, June 24, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui's budesonide enteric capsules, which were approved by the National Medical Products Administration (NMPA) in December 2025.

Pursuant to this collaboration, Hainan Herui's budesonide enteric capsules will be permitted to be launched in the Chinese mainland market, with Everest Medicines responsible for their commercialization. Everest Medicines will provide rigorous technical guidance and quality audits over Hainan Herui's manufacturing and supply processes. This collaboration is expected to enhance patient access to the combined franchise of NEFECON^® and Hainan Herui's budesonide enteric capsules. This collaboration is subject to the satisfaction of customary closing conditions.

About NEFECON^®

NEFECON^® is an oral, delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity that undergoes substantial first pass metabolism. NEFECON^® was designed as a 4 mg delayed release capsule and is enteric coated so that it would remain intact until it reaches the ileum. Each capsule contains coated beads of budesonide that target mucosal B-cells present in the ileum, including the Peyer's patches, which are responsible for the production of galactose-deficient IgA1 antibodies (Gd-IgA1) causing IgA nephropathy.

NEFECON^® was approved in November 2023 through National Medical Products Administration (NMPA)'s priority review for the treatment of primary IgA nephropathy in adults at risk of disease progression. It was subsequently included in the National Reimbursement Drug List in November 2024, and received full approval from the NMPA in April 2025, irrespective of proteinuria levels, benefiting most individuals living with IgA nephropathy.

It has been approved across all Everest Medicines' territories, including mainland China, Hong Kong SAR, Macau SAR, Taiwan region, China, as well as Singapore and South Korea.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

CHANGSHA, China, June 24, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") developed a 21-ton crawler hydraulic excavator for the extreme heat, dusty conditions and prolonged breaker operations common in the Middle East. Developed by a team led by Wu Baoshuo, deputy director of the Medium and Large Excavator Research Institute at Zoomlion Earthmoving Machinery Company, the excavator received an Outstanding Flagship Product Award at the company's Seventh Science and Technology Innovation Conference.

Designed for the Middle Eastern markets, the excavator is built for municipal construction, utility projects and mining operations, where temperatures can exceed 50 degrees Celsius and hydraulic breaker work may account for more than 70% of operating time.

"Customers in the Middle East do not simply need another excavator. They need one that can keep working," Wu said. "The conditions are very different from conventional earthmoving, so the machine has to be developed around the realities of the local jobsite."

Wu led the project from design and testing through optimization and mass production. One of the team's biggest challenges was controlling heat during prolonged breaker operations. The combination of continuous breaker work and extreme temperatures placed heavy demands on the cooling system.

The team redesigned the airflow layout and optimized the cooling core to improve heat dissipation. Engineers also strengthened key structural components and refined welds to reduce stress during repeated impact. To improve dust protection, they enhanced the air intake system and cab sealing.

The team tested each improvement at customer worksites in the Middle East, using sensors to collect data and completing thousands of breaker cycles to refine the design.

The project brought together teams across product development, testing, manufacturing, technical support and overseas operations, while Zoomlion's testing center at its headquarters supported three months of high-frequency breaker durability testing.

The development process required repeated testing and refinement. When an early cooling design needed further adjustment, the team used the data to adjust the system and move forward.

"Innovation always comes with lessons," Wu said. "The company's support gave us the confidence to keep solving tough engineering challenges."

For Wu and his team, the award recognizes years of customer-focused engineering. "It is an honor, but not the finish line," he said. "We will keep learning from the jobsite and building equipment customers can rely on."

SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP production campaign. The manufacturing process execution was completed with zero deviations, while critical process parameters remained stable and yields reached expected levels, demonstrating robust process performance and strong execution capabilities. As the 25th drug substance manufacturing facility within WuXi Biologics' global network, MFG17 is designed to provide scalable manufacturing services for a broad range of biologics across both clinical and commercial stages.

To meet the diverse needs of projects at different development stages, MFG17 is equipped with multiple single-use bioreactors (SUBs), with a total manufacturing capacity of 9,000 liters for 80-100 batches annually. While adhering to global regulatory requirements, MFG17 offers both flexibility and process adaptability, supporting a wide variety of process modes, including fed-batch, N-1 perfusion, perfusion, intensified perfusion, and fully automated continuous manufacturing. These capabilities enhance operational efficiency and process productivity, while enabling robust scale-up and reliable supply for complex biologics.

MFG17 is also advancing its digitalization strategy by systematically implementing automation, digital technologies, and advanced infrastructure across the manufacturing value chain. By transforming data, computation, and predictive modelling capabilities into smarter operational management and higher production efficiency, providing clients cost-competitive manufacturing solutions.

The facility will work in close synergy with other operations at the Fengxian site, accelerating end-to-end integration from discovery to development, from clinical to commercial manufacturing, from drug substance to drug product, enabling faster and more efficient project delivery.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "The successful completion of the first GMP production at MFG17 further strengthens our manufacturing capabilities. Leveraging highly flexible single-use technologies and continuously advancing digital capabilities, we not only provide high-quality manufacturing support for our customers, but also serve as an extension of their capabilities, empowering global partners to accelerate the delivery of innovative biologics to patients worldwide."

WuXi Biologics continues to enhance its global dual-sourcing strategy to support technology transfer, scale-up, and multi-regional registration, providing long-term, reliable, and resilient commercial supply. The company operates across China, the United States, Ireland, Germany, and Singapore, with 5 research centers, 10 development centers, and 18 manufacturing sites, including 25 drug substance facilities and 18 drug product facilities currently in operation, providing end-to-end integrated solutions and services for global partners.

As of 2025, WuXi Biologics has delivered over 2,350 drug substance batches and over 2,260 drug product batches, and passed 46 regulatory inspections worldwide, including 22 inspections by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), with a 100% success rate, no critical findings, and no data integrity issues. In an additional demonstration of consistent high-quality delivery across its global network, the company has passed more than 1,800 GMP quality audits by global clients, including over 230 audits by EU Qualified Persons.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics—from concept to commercialization—for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics is supporting 982 integrated client projects, including 78 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com. 

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts
Business
[email protected] 

Media
[email protected]

China is one of the world’s leading hubs for technology and industry, with a strong pool of talented engineers, rapid iterative innovation among developers, and remarkable growth in the scale of local enterprises, as Jensen Huang, Founder and CEO of NVIDIA Corporation (NVDA.US), delivered a video speech at the 4th China International Supply Chain Expo.

He noted that more than 1.6 million developers in China are conducting R&D based on NVIDIA’s platform. They are building practical AI technologies for manufacturing, logistics, robotics, energy, healthcare and scientific research. NVIDIA will continue to enhance its computing power platform to support developers and various industries in implementing practical AI solutions.
~

AASTOCKS Financial News
Website: www.aastocks.com

LUXSHARE PRECISION (002475.SZ) has passed the listing hearing of the Hong Kong Stock Exchange, and has begun gauging interests of investors about its Hong Kong IPO, which may raise approximately USD3 billion, Bloomberg reported, citing sources. CITIC Securities, Goldman Sachs and CICC are acting as joint sponsors.

Over the past year, LUXSHARE PRECISION's share price in Shenzhen has proliferated by more than 1x, with its market cap topping USD77 billion. As an OEM for Apple Inc. (AAPL.US) products, LUXSHARE PRECISION charted revenue of RMB332.3 billion last year, up 24% YoY.
~

AASTOCKS Financial News
Website: www.aastocks.com

Li Chenggang, China International Trade Representative and Vice Minister of Commerce, met with Apple Inc. (AAPL.US) Chief Operating Officer Sabih Khan on Monday (22nd).

The two sides exchanged views on China-US economic and trade relations, as well as Apple's development in China and other issues.
~

AASTOCKS Financial News
Website: www.aastocks.com

S&P Global announced that Alphabet Inc. (GOOGL.US) will replace Verizon Communications Inc. (VZ.US) as a constituent of the DJIA, further increasing the weighting of large-cap technology stocks among blue chips.

Alphabet Inc. inched up 0.59% to USD348.17 in after-hours trading, while Verizon Communications Inc. faded 0.6%.

S&P Global said Alphabet Inc. will become one of the 30 DJIA constituents before market open next Monday (29th). It believes the inclusion of Alphabet Inc. will enhance the DJIA’s exposure to AI, cloud computing infrastructure and advertising.
~

AASTOCKS Financial News
Website: www.aastocks.com

Completing 2G Service Cessation and Advancing to 5.5G Intelligent Communications

HONG KONG, June 23, 2026 /PRNewswire/ -- China Mobile Hong Kong Company Limited ("CMHK") today announced, with the approval of the Communications Authority ("CA"), the official cessation of its second-generation mobile communications ("2G") service. This milestone marks CMHK as the first mobile network operator in Hong Kong to provide only 4G, 5G and 5.5G high-speed mobile communications services, underscoring the Company's continued commitment to building a more efficient, intelligent and future-ready mobile network in Hong Kong.

Driving the continuous advancement of network technology

CMHK remains committed to the advancement of network technology and continuous enhancement of its network infrastructure and service capabilities. Following the cessation of its 3G service in June 2025, the completion of 2G service cessation today marks another significant milestone in the Company's network evolution. Valuable spectrum resources and related technologies will be reallocated to the development of 5G and 5.5G networks, further enhancing network capacity, coverage efficiency and intelligent management. This will bring customers a faster, lower-latency and more stable mobile communications experience, while supporting the rapid development of AI applications, the IoT, industry digitalization and smart city innovation. It will also establish a solid foundation for the long-term development of Hong Kong's network infrastructure and information technology ecosystem.

AI Technology Empowers Network Upgrade

During this network upgrade, CMHK made full use of AI technologies to optimize the entire transition process. Through big data analytics and machine learning models, the Company accurately identified 2G users and engaged them through intelligent outbound calls, SMS messages and app reminders, achieving cumulative customer reach of more than 8 million touchpoints.

In addition, CMHK leveraged its self-developed AI-powered intelligent network to help teams rapidly identify terminal compatibility and potential service needs, significantly enhancing customer service and support efficiency. Together with real-time monitoring of network quality and user experience, overall network performance remained stable throughout the process, enabling a smooth technology transition with minimal impact on customers.

Caring Support and Social Responsibility

CMHK remains committed to balancing technology advancement with social responsibility, and has established a comprehensive customer support system to ensure a smooth transition. For elderly customers using legacy devices, the Company proactively provided one-on-one on-site and remote assistance, large-print user guides, dedicated hotlines and priority service channels at retail stores, ensuring a worry-free and seamless transition for customers. The Company also introduced dedicated subsidies to support customers in replacing legacy devices, and offered free replacement of next-generation USIM cards. In addition, written notifications were sent by registered mail, while terminal device subsidies have been extended to 31 December 2026, ensuring a seamless upgrade of customers' communications experience.

The completion of 2G service cessation marks the fulfilment of a historic mission in the development of mobile communications. It also marks Hong Kong's mobile network entering a new stage of greater efficiency, intelligence and innovation. Looking ahead, CMHK will continue to focus on the core development of 5.5G, while further investing in innovative technology research and development, AI-powered network intelligence and smart city infrastructure. The Company will continue to empower the digital transformation of industries and support Hong Kong in developing into an international innovation and technology hub with global influence.

About China Mobile Hong Kong Limited

China Mobile Hong Kong Company Limited ("CMHK") is the wholly-owned subsidiary of China Mobile Limited (HKEx: 941), which is listed on the Fortune Global 500. CMHK was incepted in January 1997 and was the first mobile network operator to launch PCS services in Hong Kong.

As the world's leading mobile network brand with the largest customer base*, The Company offers innovative and comprehensive 5G communications services, including voice, data, IDD and international roaming. The Company is committed to the development of 5G with new technologies such as artificial intelligence, internet of things, cloud computing and big data, integrating 5G applications in different industries, promoting the construction and development of smart city groups in Greater Bay Area.

* China Mobile (Hong Kong) Limited is a wholly-owned subsidiary of China Mobile Limited. As of 31 December 2025, China Mobile Limited had the largest number of mobile network subscribers in the world.